X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 38.2 23.3 163.7% View Chart
P/BV x 3.9 5.9 67.0% View Chart
Dividend Yield % 0.3 0.8 40.7%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-17
CADILA HEALTHCARE
Mar-17
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs622460 135.2%   
Low Rs458305 150.3%   
Sales per share (Unadj.) Rs181.992.1 197.4%  
Earnings per share (Unadj.) Rs12.914.8 86.9%  
Cash flow per share (Unadj.) Rs29.318.5 158.6%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.40.8 44.3%  
Book value per share (Unadj.) Rs155.768.0 229.0%  
Shares outstanding (eoy) m804.511,023.74 78.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.2 71.5%   
Avg P/E ratio x42.025.8 162.6%  
P/CF ratio (eoy) x18.420.7 89.0%  
Price / Book Value ratio x3.55.6 61.7%  
Dividend payout %15.521.6 72.0%   
Avg Mkt Cap Rs m434,516391,581 111.0%   
No. of employees `00023.016.9 136.7%   
Total wages/salary Rs m26,33815,002 175.6%   
Avg. sales/employee Rs Th6,349.15,594.5 113.5%   
Avg. wages/employee Rs Th1,143.0890.1 128.4%   
Avg. net profit/employee Rs Th449.3899.9 49.9%   
INCOME DATA
Net Sales Rs m146,30294,295 155.2%  
Other income Rs m2,2871,286 177.8%   
Total revenues Rs m148,58995,581 155.5%   
Gross profit Rs m24,75819,036 130.1%  
Depreciation Rs m13,2293,750 352.8%   
Interest Rs m1,594450 354.2%   
Profit before tax Rs m12,22216,122 75.8%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,7981,289 139.5%   
Profit after tax Rs m10,35415,168 68.3%  
Gross profit margin %16.920.2 83.8%  
Effective tax rate %14.78.0 184.0%   
Net profit margin %7.116.1 44.0%  
BALANCE SHEET DATA
Current assets Rs m87,37060,223 145.1%   
Current liabilities Rs m33,08153,058 62.3%   
Net working cap to sales %37.17.6 488.4%  
Current ratio x2.61.1 232.7%  
Inventory Days Days8770 124.5%  
Debtors Days Days6288 70.7%  
Net fixed assets Rs m111,56772,984 152.9%   
Share capital Rs m1,6091,024 157.1%   
"Free" reserves Rs m123,64568,576 180.3%   
Net worth Rs m125,25469,600 180.0%   
Long term debt Rs m36,45424,684 147.7%   
Total assets Rs m209,532152,207 137.7%  
Interest coverage x8.736.8 23.5%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.70.6 112.7%   
Return on assets %5.710.3 55.6%  
Return on equity %8.321.8 37.9%  
Return on capital %8.517.9 47.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06621,280 240.0%   
Fx outflow Rs m17,67810,874 162.6%   
Net fx Rs m33,38810,406 320.9%   
CASH FLOW
From Operations Rs m23,82413,495 176.5%  
From Investments Rs m-13,127-29,103 45.1%  
From Financial Activity Rs m-13,23923,158 -57.2%  
Net Cashflow Rs m-2,4787,556 -32.8%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 15, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS